<DOC>
	<DOC>NCT01446679</DOC>
	<brief_summary>This study is to evaluate the controlling effect of atrovastatin on plasma lipid to achieve the category-specific targeted lipid levels.</brief_summary>
	<brief_title>Special Drug Use-Results Survey of Lipitor Tablets</brief_title>
	<detailed_description>To confirm the low-density lipoprotein cholesterol (LDL-C)-lowering effect of 24 weeks of treatment with LipitorÂ®(Generic Name : atorvastatin calcium) Tablets and determine the rate of achievement of the category-specific target LDL-C level in patients with hypercholesterolemia; and to confirm the usefulness (efficacy and safety) of atorvastatin in patients who have not responded sufficiently to other statin therapies</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Patients with hypercholesterolemia who have not achieved the categoryspecific target lipid level</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Lipitor</keyword>
	<keyword>HMG-CoA reductase inhibitor</keyword>
</DOC>